{
  "docId": "019de075-4481-714f-9573-a4ad96e0f148",
  "docSlug": "816ee2fbc8fb2bf52edc4f2891aaa98f",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 27 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 16,
  "pageCount": 27,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes yellow highlighting on key endpoint descriptions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4481-714f-9573-a4ad96e0f148/16",
  "deckHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148",
  "deckJsonHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148.json",
  "deckAnchorHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "list",
      "text": "Compared Sildenafil Cream vs. placebo used in patients' home setting.\nCo-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale).\nSecondary endpoint: measured change in the number of satisfactory sexual events\nExploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study. Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1feae4a0-5b37-4a64-bab1-2352ceeab985",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.86,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs. placebo over 12 weeks of double-blinded dosing following both a non-drug and placebo run-in period",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42ca55c5-b792-4ff0-9ddb-ceed7ce32dce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.58,
        "x": 0.21,
        "y": 0.708
      },
      "kind": "paragraph",
      "text": "Topline data of exploratory Phase 2b RESPOND study announced June 5, 2023.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62451b66-4211-47d1-9d12-cdec7b09bbcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.11,
        "y": 0.19
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6% - Phase 2b RESPOND Study - Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5711c394-1884-486e-b61f-17a8b51c652a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}